It has been reported that HER2 amplification in NSCLC is associated with aggressive tumor characteristics, including larger tumor size, an increased likelihood of pleural metastases, and a higher rate of lympho-vascular invasion. This evidence concerns the gene ERBB2 and neoplasm.